论文部分内容阅读
Background To assess efficacy and safety of Fondaparinux during thrombolytic therapy in acute ST-elevation myocardial infarction patients.Methods From Nov.2011 to Apr.2012,patients with acute ST-elevation myocardial infarction and pain to hospital time within 6 hours were received thrombolytic therapy by recombinant tissue-type plasminogen activator(rt-PA).